FINWIRES · TerminalLIVE
FINWIRES

$KPTI

3 stories mentioning KPTIUpdated 44d ago

Every FINWIRES story that references KPTI, newest first.

What are analysts saying about KPTI?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on KPTI?

Wire

Top Midday Decliners

Baird downgraded Karyopharm Therapeutics (KPTI) to neutral from outperform while adjusting its price target to $3 from $15.Shares slumped 71% as intraday trading volume jumped to over 15.0 million from a daily average of about 568,000.GoDaddy (GDDY) shares sank 20% amid heavy trading after the company narrowed its full year 2026 revenue guidance.More than 3.66 million shares of the company traded intraday compared with a daily average of about 2.45 million.Coinbase Global (COIN) reported a Q2 loss and a drop in year-over-year revenue late Thursday. Rosenblatt Securities adjusted the company's price target to $200 from $240 while maintaining its buy rating.Shares of Coinbase slumped 9.5% as intraday trading volume climbed to over 13.8 million from the stock's daily average of about 8.45 million.Price: $148.05, Change: $-15.53, Percent Change: -9.49%

$COIN$GDDY$KPTI
Research

Baird Downgrades Karyopharm Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $15

Karyopharm Therapeutics (KPTI) has an average rating of overweight and mean price target of $9.83, according to analysts polled by FactSet.

$KPTI
Wire

Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis

Karyopharm Therapeutics (KPTI) said Tuesday that a late-breaking abstract from its phase 3 trial of selinexor combined with ruxolitinib in myelofibrosis was accepted for an oral presentation at the 2026 European Hematology Association Congress in mid-June.The company said new data will highlight a post-hoc analysis of 24 patients from phase 1 of the trial, which indicates that achieving a spleen volume reduction of 35% or more may predict overall survival, consistent with a similar analysis from the phase 3 trial.Shares of Karyopharm Therapeutics were down more than 8% in Tuesday trading.Price: $8.99, Change: $-0.84, Percent Change: -8.50%

$KPTI

Track with the FINWIRES app suite